| --- | --- | |------------------------------------------------------|-------| | | | | AngioDynamics | | | First Quarter Fiscal Year 2025 Earnings Presentation | | | October 3, 2024 | | | --- ...

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)— Oct. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quar ...

Core Insights - AngioDynamics, Inc. is expected to report a quarterly loss of 15 cents per share for its first quarter, compared to a loss of 12 cents per share in the same period last year [1] - Projected quarterly revenue for AngioDynamics is $67.93 million [1] - The company received CE Mark approval for its Auryon System in Europe on September 3 [1] - AngioDynamics shares closed at $7.65, reflecting a gain of 0.3% [1] Analyst Ratings - HC Wainwright analyst Yi Chen has a Buy rating with a price target of $14, with an accuracy rate of 63% [2] - Oppenheimer analyst Steven Lichtman upgraded the stock to Outperform with a price target of $12, having an accuracy rate of 74% [2] - Raymond James analyst Jayson Bedford maintained an Outperform rating but reduced the price target from $12 to $10, with an accuracy rate of 71% [2] Consensus Price Target - The consensus price target for AngioDynamics is $12.25 based on ratings from four analysts [3] - The highest price target is $14 from HC Wainwright & Co., while the lowest is $10 from Raymond James [3] - Recent analyst ratings suggest an implied upside of 75.21% for AngioDynamics based on an average price target of $13.67 [3]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Marex Group plc (MRX) : This financial services platform provider has seen the Zacks Consensus Estimate for its current year earnings increasing 22.3% over the last 60 days.AngioDynamics, Inc. (ANGO) : This medical technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.8% over the last 60 days.Opera Limited (OPRA) : This internet technology company has seen the Zacks Consensus Estimate for i ...

AngioDynamics, Inc.(ANGO) has initiated the RECOVER-AV clinical trial, a prospective, multinational, single-arm study aimed at assessing the efficacy, safety and long-term outcomes of the AlphaVac Multipurpose Mechanical Aspiration F1885 System for treating acute intermediate-risk pulmonary embolism (PE).Following the success of the U.S.-based APEX-AV trial, which demonstrated significant improvements in right ventricular function and clot burden reduction, RECOVER-AV will enroll patients across 20 European ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Arcturus Therapeutics Holdings Inc. (ARCT) : This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 40.8% over the last 60 days.M/I Homes, Inc. (MHO) : This homebuilder company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.7% over the last 60 days.First Mid Bancshares, Inc. (FMBH) : This financial holding company has seen the Zacks Consensus Estimate f ...

AngioDynamics, Inc. (ANGO) has announced that its Auryon Atherectomy System has received the CE Mark. This innovative system, designed for the treatment of Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR), utilizes state-of-the-art solid-state laser technology. It stands out as the first laser atherectomy system capable of treating lesions of any type, length, or location with minimal vessel wall impact.AngioDynamics is a pioneering medical technology com ...

AngioDynamics (ANGO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

AngioDynamics (ANGO) closed the last trading session at $7.53, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.33 indicates a 77% upside potential.The average comprises three short-term price targets ranging from a low of $13 to a high of $14, with a standard deviation of $0.58. While the lowest estimate indicates an increase of 72.6% from the current price level, ...

From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves ...